After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact

Chinese biotech company Hengrui Pharma partnered with GSK plc (NYSE:GSK) on Monday to develop up to 12 medicines.

These agreements will add significant value to Hengrui’s globalization strategy and provide GSK with significant new growth opportunities beyond 2031.

The programs were selected to complement GSK’s extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline.

Also Read: GSK’s Blood Cancer Drug Review Extended As FDA Seeks More Data

GSK will pay $500 million in upfront fees across the agreements.

The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan region) for (HRS-9821) in clinical development for chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, irrespective of background therapy.

HRS-9821 has demonstrated potent PDE3 and PDE4 inhibition, leading to increased bronchodilation and anti-inflammatory effects in early clinical and preclinical ...